openPR Logo
Press release

Parkinson's Disease Therapeutics Market worth $11.64 billion by 2030, growing at a CAGR of 8.26% - Exclusive Report by 360iResearch

10-04-2023 11:57 AM CET | Health & Medicine

Press release from: 360iResearch

Parkinson's Disease Therapeutics Market | 360iResearch

Parkinson's Disease Therapeutics Market | 360iResearch

The "Parkinson's Disease Therapeutics Market by Type (Intestinal Infusion, Oral, Subcutaneous), Drug Class (Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor), Distribution Channel, End Use - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

Request Sample Copy of this Report @ https://www.360iresearch.com/library/intelligence/parkinson-s-disease-therapeutics?utm_source=openpr&utm_medium=referral&utm_campaign=sample

Market Segmentation & Coverage:

This research report categorizes the Parkinson's Disease Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Intestinal Infusion is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Dopamine Receptor Agonist is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Online Pharmacy is projected to witness significant market share during forecast period.

Based on End Use, market is studied across Clinic and Hospital. The Hospital is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Parkinson's Disease Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Parkinson's Disease Therapeutics Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acadia Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, H. Lundbeck A/S, Mylan Inc. by Viatris Inc., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals Industries Ltd., UCB S.A., and Wockhardt Limited.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Parkinson's Disease Therapeutics Market, by Type
7. Parkinson's Disease Therapeutics Market, by Drug Class
8. Parkinson's Disease Therapeutics Market, by Distribution Channel
9. Parkinson's Disease Therapeutics Market, by End Use
10. Americas Parkinson's Disease Therapeutics Market
11. Asia-Pacific Parkinson's Disease Therapeutics Market
12. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Parkinson's Disease Therapeutics Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Parkinson's Disease Therapeutics Market?
3. What is the competitive strategic window for opportunities in the Parkinson's Disease Therapeutics Market?
4. What are the technology trends and regulatory frameworks in the Parkinson's Disease Therapeutics Market?
5. What is the market share of the leading vendors in the Parkinson's Disease Therapeutics Market?
6. What modes and strategic moves are considered suitable for entering the Parkinson's Disease Therapeutics Market?

Read More @ https://www.360iresearch.com/library/intelligence/parkinson-s-disease-therapeutics?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Parkinson's Disease Therapeutics Market worth $11.64 billion by 2030, growing at a CAGR of 8.26% - Exclusive Report by 360iResearch here

News-ID: 3234460 • Views:

More Releases from 360iResearch

Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Global Treatment Demand
Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Globa …
In recent years, the silent ascent of human metapneumovirus (HMPV) infections has begun to capture significant attention within the realm of infectious diseases. As we advance in medical science, unraveling complexities of age-old pathogens like common influenza or emerging illnesses like COVID-19, a critical discourse has been emerging around HMPV. Particularly, there seems to be a burgeoning acknowledgment of its growing impact on vulnerable global populations, propelling an increased demand
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and expected to reach USD 10.06 billion in 2024, at a CAGR 7.63% to reach USD 15.71 billion by 2030.
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and …
From Appetite to Advocacy: The Rising Demand for Meat Alternatives In recent years, the global food industry has been undergoing a remarkable transformation, driven primarily by an increasing consumer demand for healthier, sustainable, and ethically sourced food products. This seismic shift has brought traditional meat alternatives and high-protein plant-based foods into the spotlight. As the world becomes more conscious of the implications of meat consumption on health and the environment, the
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 2023 and expected to reach USD 292.84 billion in 2024, at a CAGR 11.08% to reach USD 552.63 billion by 2030.
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 202 …
Unpacking the Surge in Investments and Collaborations to Bolster Mobility-as-a-Service In recent years, as urban landscapes continually evolve, a transformative shift known as Mobility-as-a-Service (MaaS) has reshaped the way we perceive transportation. Marked by the integration of various forms of transport services into a single accessible on-demand mobility solution, MaaS is rapidly gaining traction across global cities. As an emerging paradigm, it's not just shaping the future of travel but also
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 and expected to reach USD 62.23 billion in 2024, at a CAGR 9.99% to reach USD 110.34 billion by 2030.
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 …
Smart City Revolutions: Why Data Center Colocation is the Future Backbone In the era of digital transformation, urban landscapes across the globe are undergoing a seismic shift toward becoming "smart cities." The concept of a smart city revolves around using digital technology, IoT (Internet of Things), AI, and data analytics at an unprecedented scale to improve urban infrastructure, manage resources efficiently, and enhance the quality of life for citizens. A vital

All 5 Releases


More Releases for Parkinson

Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025? The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period? The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market? In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market? In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $1.43 billion
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%. Increasing Geriatric Population Driving Demand: The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,